OCTASIC-INC
17.9.2020 04:02:10 CEST | Business Wire | Press release
Panasonic Corporation, a world-leading provider of diverse electronics technologies, B2B, communications and wireless solutions, and Octasic Inc., an innovation leader in low-power programmable processors for wireless and multimedia applications, today announced the enhancement of their ongoing collaboration to develop shared eXtended Global Platform (sXGP) solutions to include 5G and Beyond 5G based wireless network products, especially for mission-critical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005982/en/
Panasonic and Octasic will combine resources and expertise to develop high-performance, high reliability, and low-latency Small Cell solutions for the cellular IoT space, applied to B2B, Non-Terrestrial Networks in Avionics and other mission-critical verticals based on Octasic's OCT3032 System-on-Chip.
The Collaboration on sXGP
Panasonic has developed an sXGP wireless base station that makes full use of the OCT3032's embedded Opus DSP technology and realizes stable communication even in environments with high interference in unlicensed bands.
The 5G Collaboration
The expanded collaboration addresses the challenging requirements of developing a new class of Small Cells to be deployed in a wireless base station platform that contributes to mission-critical applications for advanced IoT environments and non-terrestrial operations toward 5G and Beyond 5G.
Octasic’s programmable processor platform delivers on the low power requirements of Panasonic Small Cell designs and accelerates development and support of multiple air interfaces from sXGP to 3GPP. More importantly it addresses the need for deterministic air interface design to meet the challenges of implementing an ultra-reliable low-latency solution in diverse environments from private campus-wide networks, to machine or robotic communication in warehouses, to aircraft systems.
Panasonic promotes the development of Ultra-Reliable and Low-Latency Communications (URLLC) functions that comply with both 3GPP and Non-Terrestrial Network (NTN) technologies and provides Octasic with engineering expertise and resources. In addition, Panasonic will accelerate digital transformation for itself and its customers demonstrating various IoT-related applications inside and outside the company.
Hideo Ohara, Director of Panasonic Technology Department, emphasized, “We are leveraging Octasic’s OCT3032 System-on-Chip, development tools, and 4G/5G software to develop and deploy differentiated sXGP, 4G, and 5G Small Cell network products that deliver on our world-leading technical requirements for high performance, highly reliable, low latency, and low power Small Cell network products. We are delighted to advance the evolution of society with such unique systems that are the culmination of our years of technological collaboration with Octasic.”
Fabio Gambacorta, Global VP Business Development and Sales at Octasic emphasized, “Offering a world-leading System-on-Chip solution for Small Cell designs does not happen by chance; it is critical to partner with an innovative wireless network OEM like Panasonic. Octasic is proud to collaborate on not only the development of Panasonic’s first sXGP network products, but to expand this collaboration to encompass future solutions for 3GPP-compliant 4G and 5G networks, especially those requiring high reliability, low latency, and low power.”
For more information about the OCT3032 SoC and its evaluation and development platforms, please contact pr@octasic.com or visit www.octasic.com/product/oct3032w/ .
About Octasic Inc.
Founded in 1998 and headquartered in Canada, Octasic develops innovative programmable processors for mobile wireless markets such as proprietary 4G/5G-based networks. Octasic’s Opus-based processor technology, programming tools, software and reference code reduce costs, mitigate risk, accelerate time-to-market, and allow developers to focus engineering resources on their areas of differentiation. With 20 years of technology development in low-power programmable System-on-Chip solutions, Octasic products deliver a low-power, low-latency “5G Small Cell on a Chip” for both commercial and private networks. For more information, please visit http://www.octasic.com/ .
About Panasonic Corporation
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .
For media inquiries, please contact Global Communications Department:
https://news.panasonic.com/global/contacts/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom